A new analysis by Amalgamated Life’s John Thornton, published May 12, 2026 in InsuranceNewsNet, quantifies a structural gap in how self-insured employers manage GLP-1 drug costs: pharmacy benefit teams and stop-loss advisors are working on different timelines with different data, and the result is aggregate exposure that neither team sees clearly.
The numbers are stark. Per-member per-month (PMPM) allowed costs for GLP-1 weight management coverage rose roughly 840%, from $2.41 to $22.59, between 2022 and 2024. About 12% of US adults now report taking a GLP-1, according to KFF survey data from fall 2025. Injectable formulations still cost more than $10,000 per member per year.
Who It Affects
Self-insured employer health plans of all sizes, but mid-size groups (100 to 500 lives) face the sharpest aggregate risk. A 300-person group where 20% of members start GLP-1 therapy adds roughly $600,000 in annual pharmacy cost. That figure is large enough to breach many mid-size aggregate stop-loss corridors that were set using pre-2024 utilization assumptions.
Public entities, school districts, and hospital systems that self-fund employee health benefits carry the same exposure. Captives writing medical stop-loss for employer groups face the aggregate corridor squeeze from the underwriting side.
The Reserve Mechanism
The operative reserve driver is aggregate stop-loss exposure. Individual GLP-1 prescriptions at $10,000 to $15,000 per year typically fall below specific attachment points, so they rarely trigger specific stop-loss claims on their own. But sustained utilization across a growing enrolled population creates aggregate pressure that can push total plan cost above the aggregate attachment point.
This makes GLP-1 exposure harder to spot than catastrophic single-claimant events like gene therapy claims or $1 million cancer cases. The cost accumulates across many members, each below the specific threshold but collectively material.
Utilization forecasting compounds the problem. Nearly two thirds of GLP-1 patients discontinue before the 12-week mark needed for meaningful weight loss. That churn makes trend projection unreliable: new starts flood in, most stop quickly, but a growing core of adherent patients drives sustained spend. The expected claim ratio used in Bornhuetter-Ferguson projections for the pharmacy component needs to reflect this two-population dynamic, not a single blended utilization rate.
The List Price Illusion
Novo Nordisk has announced a 50% list price cut on semaglutide products, effective January 2027, bringing the list price to $675 per month. But Mercer’s analysis warns that net employer costs may not decline. The list price cut is expected to be offset by reduced rebates, leaving the net cost to self-insured plans roughly flat. Plans budgeting around headline price reductions may be understating their 2027 pharmacy reserve.
What This Means for Your Next Review
If your pharmacy benefit review and stop-loss renewal happen on separate calendars with separate advisors, GLP-1 exposure sits in the gap between them. The next reserve study or stop-loss renewal should include a scenario analysis showing aggregate corridor adequacy at 15%, 20%, and 25% GLP-1 enrollment rates. Ask your stop-loss broker whether the current aggregate attachment was priced with a GLP-1 load, and if so, what utilization rate it assumed. Advisors who bring pharmacy utilization data into the stop-loss conversation in real time will have more leverage at renewal and fewer surprises at year-end.